Compare AEI & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEI | ANIX |
|---|---|---|
| Founded | 2014 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4M | 104.0M |
| IPO Year | N/A | 1987 |
| Metric | AEI | ANIX |
|---|---|---|
| Price | $2.94 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 30.8K | ★ 233.6K |
| Earning Date | 11-14-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,108,028.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $2.33 |
| 52 Week High | $4.55 | $5.46 |
| Indicator | AEI | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 34.76 |
| Support Level | $2.39 | $2.75 |
| Resistance Level | $3.02 | $3.09 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 24.44 | 5.00 |
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.